These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15468616)

  • 1. The role of physician extenders in managing patients with chronic hepatitis C.
    Gujral H; Viscomi C; Collantes R
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S33-7. PubMed ID: 15468616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
    Ong JP; Younossi ZM
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S17-21. PubMed ID: 15468613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
    Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM
    Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation.
    Gonzalez SA; Jacobson IM
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S22-6. PubMed ID: 15468614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of hepatitis C: therapeutic management].
    Bourliere M
    Gastroenterol Clin Biol; 2008 May; 32(5 Pt 2):S166-71. PubMed ID: 18482813
    [No Abstract]   [Full Text] [Related]  

  • 6. [Quality of life of patients with chronic hepatitis C: effect of treatments].
    Couzigou P
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B257-63. PubMed ID: 12180299
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of growth factors with antiviral therapy for chronic hepatitis C.
    Curry MP; Afdhal NH
    Clin Liver Dis; 2005 Aug; 9(3):439-51, vii. PubMed ID: 16023976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of nursing in managing treatment-associated adverse effects in patients with hepatitis C.
    Leone NE
    Gastroenterol Nurs; 2002; 25(5):201-3. PubMed ID: 12394396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.
    Fabrizi F; Dixit V; Martin P; Messa P
    J Viral Hepat; 2011 Jul; 18(7):e263-9. PubMed ID: 21108701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concise review of the management of hepatitis C.
    Addesa JA; Navarro VJ
    Compr Ther; 2001; 27(4):275-83. PubMed ID: 11765685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lingual hyperpigmentation in a patient with chronic infection].
    López Peláez MV; González Díaz P; Téllez Molina MJ; Vergas García J
    Enferm Infecc Microbiol Clin; 2013 Apr; 31(4):264-5. PubMed ID: 23260387
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of epoetin alfa in maintaining ribavirin dose.
    Afdhal NH
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S25-35. PubMed ID: 15081101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anemia management in patients with chronic viral hepatitis C.
    Hynicka LM; Heil EL
    Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of chronic hepatitis C: side effects, tolerability and quality of life].
    Gournay J; Richou C
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B60-75. PubMed ID: 12180310
    [No Abstract]   [Full Text] [Related]  

  • 15. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon and ribavirin in HCV: improvement of sustained viral response.
    Ferenci P
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1109-22. PubMed ID: 19187870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chronic hepatitis C: apart from antiviral treatment what other measures should be recommended?].
    Larrey D
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B283-90. PubMed ID: 12180302
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prevention of adverse effects in ribavirin and interferon combination therapy].
    Izumi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):523-7. PubMed ID: 15359855
    [No Abstract]   [Full Text] [Related]  

  • 19. [Chronic hepatitis C: what to do if the first treatment failed?].
    Asselah T
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B50-9. PubMed ID: 12180309
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance].
    Pol S
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B264-73. PubMed ID: 12180300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.